Updated October 28, 2026 · Sources linked below
Stem cells are living cells. Exosomes are tiny cell-released vesicles that can carry biological material. Their roles in research are different, and they should not be described as interchangeable treatments for pain, aging, or recovery.
Approval applies to a specific product and use
Some cellular therapies have FDA-approved indications. In December 2024, FDA approved Ryoncil for steroid-refractory acute graft-versus-host disease in pediatric patients aged two months and older. That is a specific serious condition, not a general approval for joint injections or anti-aging treatment. [1]
It is therefore inaccurate to say that no cellular products are approved, or that approval of one validates all others. The relevant question is whether the exact product is approved for the proposed use, or is being investigated through an appropriate regulated pathway.
Exosome marketing needs particular scrutiny
FDA states that there are no FDA-approved exosome products. The agency has warned about unapproved products and associated safety concerns. [2] Claims that an exosome product regenerates cartilage, reverses aging, or treats a broad range of diseases require evidence; the word “cell-free” does not establish safety.
FDA registration, a clinical-trial listing, or a laboratory certificate is not the same as product approval. Those distinctions can be obscured in promotional material. [3]
Ask about outcomes and accountability
A credible explanation should identify the product, intended indication, human evidence, known risks, and follow-up arrangements. For an investigational treatment, ask who oversees the study and what protections apply. A testimonial cannot establish that a treatment caused improvement.
Patient questions
- What is the exact product, and where can I verify its regulatory status?
- Does the evidence concern my condition and the proposed delivery route?
- What established alternatives should I consider?
- Who manages complications, and what costs could follow?
Research in regenerative medicine is important. Accurate education makes room for that research while keeping product-specific approvals and unsupported commercial claims clearly distinguished.
How does PRP compare?
PRP is prepared from a patient’s own blood and concentrates platelets. It is not a stem-cell or exosome product. Research findings depend on the condition and procedure; these treatments should not be presented as interchangeable. AAOS explains PRP and the limits of the evidence.
Prepare for a conversation about your options
Our patient guide to exosomes, stem cells and PRP provides a side-by-side explanation and six questions to bring to an appointment. Meet Dan McCarthy, PA, OlympusMD’s Director of Regenerative Medicine & Anti-Aging, and explore PRP consultations in Milton.
Have questions about care at OlympusMD? Call (470) 359-4815 to discuss your goals and the appropriate next appointment.
Sources and further reading
- FDA: Ryoncil approval for pediatric steroid-refractory acute graft-versus-host disease, December 18, 2024
- FDA: public safety alert on unapproved stem-cell and exosome products
- FDA: patient information about regenerative medicine therapies
Patient education from OlympusMD Wellness in Milton, Georgia. This article provides general information and does not replace an individual medical evaluation.
